IMATINIB

imatinib 100 mg capsule, 60
Manner of administration:Oral
General Schedule
Authority Required

Restriction

Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Initial treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 60 # of repeats: 5 DPMQ: $97.83 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
ARX-IMATINIB
IMATINIB-DRLA
imatinib 100 mg capsule, 60
Manner of administration:Oral
General Schedule
Authority Required

Restriction

Indication: Myelodysplastic or myeloproliferative disorder
Treatment phase: Initial treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 60 # of repeats: 5 DPMQ: $97.83 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
ARX-IMATINIB
IMATINIB-DRLA

IMATINIB (10920R)

Supply only until 01/10/2027
imatinib 100 mg capsule, 60
Manner of administration:Oral
General Schedule
Authority Required

Restriction

Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Initial treatment - first-line therapy

Restriction

Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Initial treatment - first-line therapy
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 60 # of repeats: 2 DPMQ: $97.83 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
ARX-IMATINIB
IMATINIB-DRLA
imatinib 100 mg capsule, 60
Manner of administration:Oral
General Schedule
Authority Required

Restriction

Indication: Acute lymphoblastic leukaemia
Treatment phase: Induction and Consolidation therapy
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 60 # of repeats: 2 DPMQ: $97.83 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
ARX-IMATINIB
IMATINIB-DRLA
imatinib 100 mg capsule, 60
Manner of administration:Oral
General Schedule
Authority Required

Restriction

Indication: Aggressive systemic mastocytosis with eosinophilia
Treatment phase: Initial treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 60 # of repeats: 5 DPMQ: $97.83 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
ARX-IMATINIB
IMATINIB-DRLA
imatinib 100 mg capsule, 60
Manner of administration:Oral
General Schedule
Authority Required

Restriction

Indication: Chronic eosinophilic leukaemia or Hypereosinophilic syndrome
Treatment phase: Initial treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 60 # of repeats: 5 DPMQ: $97.83 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
ARX-IMATINIB
IMATINIB-DRLA
imatinib 100 mg capsule, 60
Manner of administration:Oral
General Schedule
Authority Required

Restriction

Indication: Dermatofibrosarcoma protuberans
Treatment phase: Initial treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 60 # of repeats: 5 DPMQ: $97.83 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
ARX-IMATINIB
IMATINIB-DRLA
imatinib 100 mg capsule, 60
Manner of administration:Oral
General Schedule
Authority Required (STREAMLINED)

Restriction (Streamlined authority code: 17960)

Indication: Myelodysplastic or myeloproliferative disorder
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 60 # of repeats: 5 DPMQ: $97.83 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
ARX-IMATINIB
IMATINIB-DRLA
imatinib 100 mg capsule, 60
Manner of administration:Oral
General Schedule
Authority Required (STREAMLINED)

Restriction (Streamlined authority code: 17885)

Indication: Chronic eosinophilic leukaemia or Hypereosinophilic syndrome
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 60 # of repeats: 5 DPMQ: $97.83 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
ARX-IMATINIB
IMATINIB-DRLA
imatinib 100 mg capsule, 60
Manner of administration:Oral
General Schedule
Authority Required (STREAMLINED)

Restriction (Streamlined authority code: 17884)

Indication: Dermatofibrosarcoma protuberans
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 60 # of repeats: 5 DPMQ: $97.83 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
ARX-IMATINIB
IMATINIB-DRLA